Wednesday, November 18, 2009

Patients Taking VIMOVO(TM) Showed A Decrease In Incidence Of NSAID-Associated Ulcers

AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

No comments:

Post a Comment